| Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn's and colitis epidemiology study SC Ng, W Tang, JY Ching, M Wong, CM Chow, AJ Hui, TC Wong, ... Gastroenterology 145 (1), 158-165. e2, 2013 | 895 | 2013 |
| Environmental risk factors in inflammatory bowel disease: a population-based case-control study in Asia-Pacific SC Ng, W Tang, RW Leong, M Chen, Y Ko, C Studd, O Niewiadomski, ... Gut 64 (7), 1063-1071, 2015 | 411 | 2015 |
| Population density and risk of inflammatory bowel disease: a prospective population-based study in 13 countries or regions in Asia-Pacific SC Ng, GG Kaplan, W Tang, R Banerjee, B Adigopula, FE Underwood, ... Official journal of the American College of Gastroenterology| ACG 114 (1 …, 2019 | 229 | 2019 |
| Early course of inflammatory bowel disease in a population-based inception cohort study from 8 countries in Asia and Australia SC Ng, Z Zeng, O Niewiadomski, W Tang, S Bell, MA Kamm, P Hu, ... Gastroenterology 150 (1), 86-95. e3, 2016 | 131 | 2016 |
| Asia–Pacific Crohn’s and Colitis Epidemiologic Study (ACCESS) Study Group. Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn’s … SC Ng, W Tang, JY Ching, M Wong, CM Chow, AJ Hui, TC Wong, ... Gastroenterology 145 (1), 158-165, 2013 | 127 | 2013 |
| Epidemiology, natural history, and risk stratification of Crohn's disease S Aniwan, SH Park, EV Loftus Gastroenterology Clinics 46 (3), 463-480, 2017 | 125 | 2017 |
| Update on the natural course of fistulizing perianal Crohn’s disease in a population-based cohort SH Park, S Aniwan, W Scott Harmsen, WJ Tremaine, AL Lightner, ... Inflammatory bowel diseases 25 (6), 1054-1060, 2019 | 109 | 2019 |
| Increased risk of acute myocardial infarction and heart failure in patients with inflammatory bowel diseases S Aniwan, DS Pardi, WJ Tremaine, EV Loftus Jr Clinical Gastroenterology and Hepatology 16 (10), 1607-1615. e1, 2018 | 105 | 2018 |
| Incidence of inflammatory bowel disease by race and ethnicity in a population-based inception cohort from 1970 through 2010 S Aniwan, WS Harmsen, WJ Tremaine, EV Loftus Jr Therapeutic advances in gastroenterology 12, 1756284819827692, 2019 | 99 | 2019 |
| Retrospective analysis of safety of vedolizumab in patients with inflammatory bowel diseases J Meserve, S Aniwan, JL Koliani-Pace, P Shashi, A Weiss, D Faleck, ... Clinical Gastroenterology and Hepatology 17 (8), 1533-1540. e2, 2019 | 88 | 2019 |
| The secondary quality indicator to improve prediction of adenoma miss rate apart from adenoma detection rate S Aniwan, P Orkoonsawat, V Viriyautsahakul, P Angsuwatcharakon, ... Official journal of the American College of Gastroenterology| ACG 111 (5 …, 2016 | 78 | 2016 |
| Development and validation of clinical scoring tool to predict outcomes of treatment with vedolizumab in patients with ulcerative colitis PS Dulai, S Singh, NV Casteele, J Meserve, A Winters, S Chablaney, ... Clinical Gastroenterology and Hepatology 18 (13), 2952-2961. e8, 2020 | 69 | 2020 |
| Combination of EUS‐FNA and elastography (strain ratio) to exclude malignant solid pancreatic lesions: A prospective single‐blinded study P Kongkam, N Lakananurak, P Navicharern, T Chantarojanasiri, K Aye, ... Journal of gastroenterology and hepatology 30 (11), 1683-1689, 2015 | 68 | 2015 |
| Antibiotic use and new-onset inflammatory bowel disease in Olmsted County, Minnesota: a population-based case-control study S Aniwan, WJ Tremaine, LE Raffals, SV Kane, EV Loftus Jr Journal of Crohn's and Colitis 12 (2), 137-144, 2018 | 64 | 2018 |
| Asia-Pacific Crohn's and Colitis Epidemiology Study ACCESS Group. Environmental risk factors in inflammatory bowel disease: a population-based case-control study in Asia-Pacific SC Ng, W Tang, RW Leong, M Chen, Y Ko, C Studd, O Niewiadomski, ... Gut 64 (7), 1063-1071, 2015 | 61 | 2015 |
| Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease M Bohm, R Xu, Y Zhang, S Varma, M Fischer, G Kochhar, B Boland, ... Alimentary Pharmacology & Therapeutics 52 (4), 669-681, 2020 | 60 | 2020 |
| Shorter disease duration is associated with higher rates of response to vedolizumab in patients with Crohn’s disease but not ulcerative colitis DM Faleck, A Winters, S Chablaney, P Shashi, J Meserve, A Weiss, ... Clinical Gastroenterology and Hepatology 17 (12), 2497-2505. e1, 2019 | 60 | 2019 |
| A combination of clinical risk stratification and fecal immunochemical test results to prioritize colonoscopy screening in asymptomatic participants S Aniwan, R Rerknimitr, P Kongkam, N Wisedopas, Y Ponuthai, ... Gastrointestinal endoscopy 81 (3), 719-727, 2015 | 51 | 2015 |
| Comparative safety and effectiveness of vedolizumab to tumor necrosis factor antagonist therapy for ulcerative colitis D Lukin, D Faleck, R Xu, Y Zhang, A Weiss, S Aniwan, S Kadire, G Tran, ... Clinical Gastroenterology and Hepatology 20 (1), 126-135, 2022 | 46 | 2022 |
| Vedolizumab drug level correlation with clinical remission, biomarker normalization, and mucosal healing in inflammatory bowel disease B Al-Bawardy, GP Ramos, MAV Willrich, SM Jenkins, SH Park, S Aniwan, ... Inflammatory bowel diseases 25 (3), 580-586, 2019 | 46 | 2019 |
